Day 2 of this yr’s Hashish Europa began on a extra sombre tone, with delegates paying their respects to medical hashish campaigner, and maybe essentially the most consequential determine within the UK’s {industry}, Hannah Deacon.
Her shut buddies and colleagues, Matt Hughes, the Co-Founder and CEO of Medcan Household Basis, and Professor Mike Barnes, Director of Maple Tree Consultancy, took to the stage to share their reminiscences of Hannah and recognise the affect she has had on numerous households all through her profession.
Each audio system spoke of her energy and dedication, noting that with out her tireless marketing campaign to make sure entry to therapy for her son and others affected by his situation, ‘we wouldn’t be right here at the moment’.
Matt spoke of all she had taught him about energy and management within the face of hardship, stating that whereas ‘we deeply miss her presence, her legacy and contribution lives on on this {industry}.
“It’s exhausting to imagine she’s now not with us. However her spirit and her work proceed to resonate. Whereas we deeply miss her presence, her legacy continues to thrive in each nook of this sector. As we transfer ahead, Hannah’s reminiscence in continues within the work that she began, in upholding the values she championed and striving for the excellence she employed.”
Professor Barnes added that in his view, Hannah’s marketing campaign to legalise medical hashish in 2018 was the one most consequential effort to vary a legislation there had been, and its success was all the way down to her attribute kindness.
“I’m so proud and so privileged to have identified her, and the {industry} as it’s at the moment wouldn’t exist with out Hannah. She was a very outstanding one that gave a lot to society in such a short while.”
Under, we’ve summarised the important thing insights from the colourful and various discussions all through Day 2 of Hashish Europa 2025. When you’re eager to dive into the small print, we’ll be exploring every session in additional element over the approaching weeks.
You may learn Day 1: Half 1 and Half 2 right here.
A Sleeping Big? A Deep Dive into the Potential of the UK Market
Prohibition Companions‘ Senior Analysts, Lawrence Purkiss and Alex Khourdaji have been joined by main hashish economics analyst Beau Whitney on the principle stage to discover their just lately launched white paper, accessible completely to Hashish Europa delegates, delving into the present state and potential of the UK’s market.
The staff additionally introduced the launch of their newest undertaking, the Prohibition Companions’ ‘Insights Hub’, an interactive web site up to date in actual time, providing free entry to all the newest knowledge on the European hashish {industry}, which is now accessible right here.
Two international markets — and the UK’s rising function
-
Lawrence Purkiss described the worldwide hashish market as break up into two spheres: the US and the remainder of the world.
-
The UK is now the fourth-largest medical hashish market globally, having surpassed Israel and approaching parity with Canada.
-
Prescribed objects have elevated fivefold between January 2022 and Could 2024. Progress is now monitoring intently with Germany, each in pace and scale.
Non-public market development, however exterior the NHS
-
The UK market is solely personal, with no NHS reimbursement, putting the monetary burden squarely on sufferers.
-
Clinics should give attention to particular indications, and prescribing medical doctors should be on the specialist register. This creates a extremely regulated however slim pool of practitioners.
-
Telehealth has been crucial, permitting a small variety of medical doctors to serve a geographically dispersed affected person base.
Unmatched product variety, aggressive pricing
-
Alex Khourdaji reported that the UK leads Europe in product variety, with over 400 accessible SKUs — largely flower, but in addition extracts, vapes, and edibles.
-
Common flower pricing stands at €8.30/g, barely above Germany, with vital variance.
-
Regardless of a comparatively small affected person base (~60,000–75,000 sufferers), which means there’s rising competitors.
Persistent structural obstacles
-
Stigma and restrictive prescribing guidelines restrict the variety of authorised medical doctors (approx. 174).
-
Bureaucratic import necessities, particularly shipment-by-shipment licensing, drive up prices and burden healthcare suppliers.
-
Advertising and marketing restrictions suppress each affected person consciousness {and professional} engagement, making affected person acquisition difficult.
World comparisons and cautionary tales
-
Whereas Germany garners most consideration, the UK is catching up rapidly in development and accessibility, even with out NHS integration.
-
Classes from Australia, Germany, and Poland warn towards fast telehealth enlargement with out regulatory safeguards, which might set off public and political backlash.
Measured development and cautious optimism
-
Beau Whitney (Whitney Economics) highlighted the mismatch between public well being ambition and accessible knowledge, calling it ironic that governments cite schooling gaps, but create the insurance policies that forestall it.
-
Progress is anticipated to proceed steadily, with the UK’s managed mannequin probably defending its long-term legitimacy.
-
Small-scale reforms like simplifying import guidelines and increasing prescriber schooling are politically possible and will considerably improve entry.
-
Nonetheless, mainstream coverage reform stays unlikely within the close to time period. For now, the emphasis should be on proof gathering, system refinement, and preserving credibility.
The Infrastructure of Entry: Can Europe Scale to five,000,000 Medical Hashish Sufferers?
As Europe inches nearer to a possible medical hashish affected person base within the thousands and thousands, this panel tackled what scaling actually requires — past laws. From digital prescribing to produce chain stability, clinician schooling to affected person belief, audio system drew on worldwide expertise to warning that development with out infrastructure dangers dropping hard-won legitimacy. The message was clear: programs should evolve as quick as coverage, or danger breaking underneath demand.
From potential to strain: constructing the infrastructure for scale
-
Sarah Sinclair (Hashish Well being) opened with a mirrored image on momentum: numbers like 5m sufferers as soon as appeared aspirational, however now the problem shouldn’t be if scale is feasible, however how briskly we will attain it.
-
Liam McGreevy (VOR Group) famous that GP prescribing in Australia was a significant catalyst for enlargement, displaying how regulatory shifts can quickly unlock entry.
Reaching Europe’s potential addressable market
-
Niall Ivers (Cantourage° UK) projected that 5 million sufferers throughout Europe would solely characterize the pilot part, with the true addressable market doubtlessly as excessive as 70–80 million, or 5% of the inhabitants.
-
Nonetheless, he pressured that affected person belief, schooling, and physician coaching stay main obstacles, together with the truth that many UK medical doctors nonetheless aren’t taught in regards to the endocannabinoid system.
The necessity for system-wide instruments and coaching
-
Eidan Havas (The Entourage Impact) pointed to digital prescribing as an important enabler. In Australia, this transition led to a significant uptake and diminished friction for pharmacies and sufferers.
-
Berta Kaguako (EthVida) warned that importing a “tickbox” mannequin of healthcare dangers undermining care high quality. She strongly advocated for a patient-focused therapy mannequin, underpinned by correct medical governance and prescriber schooling.
Oversupply, over selection, and system fatigue
-
Havas highlighted that Australia now has over 2,000 SKUs, which has led to provider competitors, clinician overwhelm, and market saturation.
-
The oversupply dynamic, particularly between home growers and cheaper Canadian imports, is creating inside tensions. If governments act, he warned, import restrictions might be on the desk.
Provide chain and affected person fallout
-
Kaguako stated provide chain breakdowns are nonetheless costing affected person well being and market credibility. When sufferers don’t obtain drugs on time, they lose belief and should drop out of therapy altogether.
-
She additionally raised severe considerations in regards to the “aftermath” of being a hashish affected person: stigma in A&E, roadside drug exams, landlord discrimination, all of which have to be addressed in parallel with scaling entry.
Prescriber vs patient-led selection — a rising debate
-
Havas cautioned towards sufferers deciding on their very own remedies, warning this might erode medical belief and isn’t seen in different areas of healthcare.
-
McGreevy countered that shared decision-making is already frequent in remedies like antidepressants.
-
Ivers added that data gaps amongst medical doctors have compelled sufferers to grow to be higher knowledgeable than prescribers, creating stress over who leads therapy choices.
Classes from overseas — and paths to keep away from
-
Ivers and Havas each pressured the significance of studying from the missteps of Australia and Germany, together with unregulated telemedicine development, lack of forecasting, and regulatory whiplash.
-
Establishing worldwide tips, standardising prescribing frameworks, and constructing programs earlier than demand spikes have been all flagged as crucial subsequent steps.
New Codecs, New Frontiers: How Drinks, Edibles and Oils Are Redefining Hashish Consumption
As hashish regulation matures throughout Europe and North America, so too does the best way hashish is consumed and marketed. This panel explored how rising product codecs — from CBD seltzers to low-THC edibles — are shifting hashish from counterculture to client product.
Past the dispensary: hashish meets mainstream client tradition
-
Jake Bullock (Cann) famous that when Cann launched, low-dose THC was met with confusion in a market dominated by high-THC flower. Now, his model is outselling alcoholic drinks and vitality drinks in some US retailers — pushed by demand for alcohol options with safer, extra predictable results.
-
Cameron Clarke (Sunderstorm/KANHA) added that hemp-derived merchandise modified the sport, particularly for customers reluctant to enter dispensaries. With shelf area in dispensaries costly and restricted, hemp-based distribution opened up entry and broadened the shopper base.
CBD as a gateway to belief and wellness branding
-
Eoin Keenan (Goodrays) described how his firm deliberately positioned its CBD seltzer as a wellness product, and has even outsold Coca-Cola in a single UK retailer. He sees CBD as a robust software for reframing hashish, notably for customers nonetheless cautious of THC.
-
Clarke emphasised that his model has all the time thought-about itself a wellness model, even when hashish tradition leaned closely towards leisure or medical use.
The strategic pivot towards practical drinks and low-dose codecs
-
Bullock argued that new hashish codecs enchantment to individuals who’ve had damaging experiences with high-THC merchandise, providing a gentler reintroduction and a social different to alcohol.
-
Keenan echoed this, suggesting that for a lot of customers, a hashish drink fills the identical area as a glass of wine — minus the hangover and stigma.
Regulatory issues: limits and alternatives
-
With the UK’s 10mg ADI (acceptable each day consumption) ceiling nonetheless in place for CBD merchandise, Keenan warned that this regulatory cap must be raised to help class development. He urged stakeholders to watch upcoming choices from the Meals Requirements Company (FSA) intently.
How Medical Hashish Can Save the NHS £4bn
Within the midst of a sluggish UK economic system, rising NHS ready lists, and an increasing welfare invoice, this Greenhouse session made the case that prescribing medical hashish for power ache is not only clinically helpful, it might be economically transformative. Presenting a their report, ‘The economics of prescribing hashish for power ache’, the Hashish Business Council argued that integrating hashish into NHS therapy protocols might result in multi-billion-pound financial savings, whereas additionally decreasing opioid dependency, bettering affected person outcomes, and rising productiveness.
Continual ache: a nationwide burden with a scalable resolution
-
Dr Shanna Marrinan outlined the size of the issue: power ache impacts over 43% of UK adults, with round 5.45 million experiencing reasonable to extreme signs.
-
Medical hashish has proven sturdy efficacy, particularly the place opioids are now not advisable, making it a viable different for one of many NHS’s most burdensome therapy areas.
A cheap therapy, regardless of greater upfront prices
-
The York Well being Economics Consortium developed a dynamic, UK-specific mannequin accounting for NHS pricing, session prices, and broader therapy patterns.
-
Whereas medical hashish incurs greater preliminary prices (session and product pricing), it results in diminished reliance on physiotherapy, CBT, and repeat appointments, finally saving the NHS £332 per affected person per yr.
Financial affect: over £5.6 billion in potential financial savings
-
When extrapolated throughout the eligible power ache inhabitants, the mannequin predicts an annual financial saving of £5.65 billion.
-
These financial savings usually are not restricted to healthcare budgets, additionally they stem from fewer misplaced workdays, with sufferers gaining a mean of 27.5 extra working hours per yr, higher mobility, sleep, and total high quality of life.
Structural and institutional challenges
-
Mike Morgan-Giles (Hashish Business Council) emphasised that NICE at the moment depends on RCTs, which are sometimes poorly suited to hashish, limiting NHS adoption.
-
Anne Schlag, who additionally labored on the report, reportedly discovered knowledge entry tough, underlining a broader downside: even proving the worth of hashish therapy stays a bureaucratic problem.
-
The present system is not only medically conservative — it’s costly, inefficient, and unsustainable.
Hurt discount and broader public well being advantages
-
Callie Seaman, one other contributor pressured the hurt discount angle, notably diminished opioid dependency, additional bolstering the case for reform.
The World Hashish Summit White Paper
From blame to duty the {industry} should lead
-
Stephen Murphy (Prohibition Companions) stated 2025 is about empowerment and accountability: somewhat than blaming regulators or politicians for gradual progress, {industry} stakeholders should supply tangible options.
-
William Muecke (Artemis Progress Companions) echoed this, warning that with out industry-led consensus, regulation will default to reactive and inconsistent policymaking, as seen within the divided U.S. market, the place hemp and hashish factions compete somewhat than cooperate.
The World Hashish Regulatory Summit: constructing a framework
-
The GCRS was launched to deliver regulators collectively, not for industrial promotion, however for closed-door, expert-driven dialogue.
-
The primary summit included representatives from 16 nations, the Worldwide Narcotics Management Board, and US federal officers, producing a white paper that serves as an early blueprint for harmonised international regulation.
Key rules from the white paper
-
The framework encourages standardisation of dosage, high quality, and medical protocols, borrowing from well-established pharma {industry} norms (e.g., ISO, ASTM, USP).
-
It stresses that GMP alone shouldn’t be sufficient — hashish should combine into current medical and client security programs.
-
A non-governmental, self-regulating physique is now in growth to hold this ahead, appearing as a bridge between {industry}, regulators, the UN, and WHO.
Avoiding fragmentation, prioritising sufferers
-
The imaginative and prescient is for a globally aligned system that also respects nationwide variations — specializing in affected person wants, science, and reimbursement.
-
Muecke highlighted Ukraine’s recognition of PTSD therapy wants for example of how knowledge and international collaboration can shift nationwide approaches.
-
The objective is regulatory alignment that facilitates belief, allows entry, and helps scalable innovation, somewhat than repeating the disjointed US mannequin.
Subsequent steps: suggestions and {industry} participation
-
Business gamers are inspired to obtain the white paper, stress-test it towards their enterprise fashions, and submit suggestions.
-
The white paper shouldn’t be a completed framework, however a place to begin for dialogue, collaboration, and eventual formalisation into worldwide regulatory finest practices.
Evolution or Overkill?: Rethinking EU-GMP Necessities in Hashish Operations
Again to the Major Stage, this session tackled the complicated actuality behind high quality assurance, product integrity, and post-harvest processing, and requested whether or not pharmaceutical-grade necessities are important on the cultivation stage, or whether or not they create pointless burdens that danger excluding credible producers.
Standardisation vs. flexibility — a balancing act
-
Arthur de Cordova (Ziel) emphasised that no post-harvest course of leaves the plant unchanged, it’s about managing the trade-offs. He warned towards myths of “no change” processes and famous that higher upstream requirements cut back the necessity for downstream remediation.
-
Timo Bongartz (Cannavigia) added that rigorous software-based monitoring is important for making certain batch consistency, bettering high quality over time, and sustaining belief throughout workers turnover and provide chain modifications.
EU-GMP: imperfect however vital?
-
Sasho Stefanoski (PHCANN Worldwide) acknowledged EU-GMP isn’t flawless, however stated it’s at the moment the best normal for pushing operational high quality and consistency.
-
GMP regulation could also be demanding, nevertheless it additionally forces enhancements in processes, creating the form of standardisation pharma expects — an important step in gaining wider {industry} credibility.
Knowledge, traceability, and provide chain integrity
-
Timo framed knowledge traceability as a aggressive differentiator, not only for compliance, however for constructing belief and separating the authorized {industry} from the black market.
-
Stefanoski pressured that for pharma, origin doesn’t matter, security and consistency do. Belief is constructed not by the place one thing is grown, however by the way it’s documented, examined, and dealt with.
Stability testing and shelf life: the lacking normal
-
With lengthy worldwide provide chains, shelf life turns into a crucial issue. Stefanoski argued for necessary stability testing, together with THC degradation knowledge, to make sure transparency and accuracy in shelf-life claims.
Professionalism and harmonisation are the following frontier
-
Stefanoski stated now could be the second to lift skilled requirements throughout the board, advocating for the harmonisation of high quality programs to assist hashish achieve full acceptance within the pharmaceutical {industry}.
-
De Cordova warned that if the US ever federalises, its inconsistent cultivation requirements would make it tough to compete with Europe’s EU-GMP ecosystem.
Pharma mindset: recollects, duty, and danger
-
De Cordova, drawing on his pharma background, highlighted the significance of product recall protocols — not only for compliance, however for constructing actual accountability. He pressured that monitoring ought to transcend origin tales and act as a security web for sufferers and regulators alike.
Advancing Medical Hashish: Prioritizing Affected person Outcomes
As Europe walks the tightrope between leisure entry and medical legitimacy, this session made the case {that a} patient-first mannequin should paved the way. Drawing from deep medical expertise in ache administration and real-world affected person outcomes, the dialogue highlighted the pressing want for schooling, innovation, and knowledge assortment to guard and progress medical hashish as a reliable therapy pathway — even because the strains with adult-use proceed to blur.
Medical expertise redefines hashish perceptions
-
Dr Simon Tordoff shared that after 25 years working in ache administration, prescribing hashish has had essentially the most dramatic affect on his follow, providing reduction to sufferers the place conventional medication had failed.
-
He started as a hashish sceptic, however real-world outcomes led him to grow to be a powerful advocate — notably for cautious sufferers beforehand compelled to self-medicate.
Grownup-use legalisation: double-edged sword?
-
Aras Azadian argued that adult-use legalisation has undermined the medical hashish mannequin, blurring the strains between the 2 and decreasing give attention to sufferers.
-
Tordoff echoed this concern, warning that leisure entry dangers marginalising reliable therapeutic use, and stressing the necessity to proactively educate sceptical medical doctors.
Shifting codecs mirror medical wants
-
A rising variety of cannabis-naïve sufferers choose oil over flower, and clinicians are more and more turning to grease for its titratability and perceived security.
-
Vape cartridges have been highlighted as a fast-growing possibility, discreet, odourless, and simple to make use of, serving to sufferers keep compliant and decreasing stigma.
-
Azadian framed this evolution as a product lifecycle: flower as Hashish 1.0, oil as 2.0, and titratable, dose-consistent codecs as 3.0, important for broader medical acceptance.
Proof: reverse translational science and real-world knowledge
-
Dr Tordoff pressured the significance of gathering real-world proof alongside RCTs, particularly for measuring quality-of-life enhancements like sleep, sociability, and emotional wellbeing — not simply ache scores.
-
Azadian famous that hashish may even enhance outcomes for sufferers’ households, and requested how the sector can generate instruments to trace these outcomes and produce extra prescribers onboard.
Who takes duty for the proof hole?
-
Each audio system questioned whether or not governments will meaningfully spend money on medical research, as an alternative urging {industry} to take the lead in constructing real-world knowledge frameworks.
-
Tordoff concluded that with 70,000 energetic sufferers, the medical hashish group already has the size to generate compelling real-world knowledge, if it commits to gathering and analysing it systematically.
